Choosing Biologics with Confidence in IBD: A Patient’s Journey from Diagnosis to Remission - Episode 5
Treatment Goals and Long-Term Remission in IBD
Crohn’s patient shares how switching to golimumab brings fast relief, safer monitoring, and a return to normal meals after biologic worries.
In this episode, “Treatment Goals and Long-Term Remission in IBD,” the expert faculty explore the short-term, intermediate, and long-term goals associated with treating inflammatory bowel disease (IBD) and discuss how clinicians monitor patients throughout the treatment journey. The panel reviews how advanced therapies can help patients achieve early symptom improvement, while also emphasizing the importance of objective disease monitoring through biomarkers, laboratory testing, and endoscopic evaluation. Expert faculty explain how markers such as fecal calprotectin, C-reactive protein (CRP), blood counts, and endoscopic healing are used to assess disease control and guide treatment decisions over time.
Throughout the discussion, the panel highlights the evolving goals of IBD management, including symptom relief, reduction of inflammation, endoscopic healing, and histologic remission. Expert faculty also discuss how these treatment targets help inform individualized care plans and improve long-term outcomes for patients living with Crohn’s disease and ulcerative colitis. In addition, the conversation examines the role of IL-23 inhibitors in long-term disease management and reviews some of the factors that influence biologic selection in clinical practice.
Using a patient case discussion, expert faculty explain why guselkumab was selected over other IL-23 inhibitors, including considerations related to treatment flexibility, route of administration, safety profile, and patient lifestyle preferences such as travel. The panel also highlights the importance of timely access to therapy and individualized treatment planning to support long-term remission and quality of life in patients with IBD.
The next episode in this series, “Long-Term Management and Monitoring in IBD,” features the panelists discussing the importance of long-term biologic therapy, treatment adherence, and ongoing disease monitoring in patients with IBD. The panel will also highlight how objective disease markers, patient communication, and individualized treatment decisions support sustained remission and quality of life.
